JWJian Wang

Jian Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jian Wang has a total of 73 co-authors. Here are the top co-authors by number of shared publications:

  • Aili Suo

    Medical Oncology, The First Affiliated hospital of Xi’an Jiaotong University, Xi’an, China

    1 shared publication
  • Aiqin Gao

    Department of Thoracic Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China

    1 shared publication
  • Bi-Hong Zhang

    Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China :

    1 shared publication
  • Bingyang Yan

    Department of Thoracic Surgery, Tangdu Hospital The Fourth Military Medical University Xi'an China

    1 shared publication
  • Chao Wu

    Department of Infectious Disease, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China

    1 shared publication
  • Chengjun Wang

    Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine Shandong University Jinan China

    1 shared publication

Latest Publications

  • Open Access

    Efficacy and Safety of First‐Line Treatment Options for Oncogene Wild‐Type Lung Adenocarcinoma With Liver Metastases

    by Jie Li, Yihui Ge, Qiaohong Liu, Xiaojuan Wei, Jian Wang, Xiufen Wang, Dahai Wang, Jiannan Liu, Yuping Sun, Aiqin Gao

    Objective: Liver metastasis represents one of the frequent drivers for cancer‐related mortality in lung adenocarcinoma. For advanced lung adenocarcinoma harboring wild‐type oncogene drivers, chemotherapies in combination with immune checkpoint inhibitors (ICIs) and/or bevacizumab (named IC, BC, and IBC, respectively) are alternative first‐line schemes as recommended by canonical treatment guidelines. However, due to the immunosuppressive tumor microenvironment in the liver, patients with liver metastases are less effective to ICIs. For this subpopulation, the optimal regimen is still undetermined. Methods: In this retrospective multicenter cohort study, treatment‐naïve lung adenocarcinoma patients with wild‐type oncogene drivers and liver metastases were enrolled from 4 cancer centers between January 2018 and December 2023. All these patients received BC, IC, or IBC as the first‐line therapies. Propensity Score Matching (PSM) was applied to balance baseline covariates. Kaplan‐Meier survival analysis, log‐rank tests, and Cox proportional‐hazards regression were used to compare PFS and OS among groups. Results: A total of 191 Patients were enrolled, in which 70 (36.6%) received IC treatment, 70 (36.6%) received BC and 51 (26.7%) received IBC treatment. After PSM, 135 eligible patients were selected, including 45 Patients in each group. IBC group showed a slightly higher ORR (44.4%) and significantly higher DCR (95.6%, p = 0.013) compared with BC (ORR = 37.2%, DCR = 81.4%) and IC (ORR = 38.5%, DCR = 71.8%) groups, as evaluated by the primary lung lesions. When liver metastases were used as target lesions, similar response was observed. The median progression‐free survival (mPFS) in patients receiving IBC (8.48 months, 95% CI: 5.98–16.10 months) was significantly longer than those receiving BC (5.09 months, 95% CI: 3.55–7.46 months) and IC (4.86 months, 95% CI: 3.06–7.82 months) (IBC vs. BC: HR = 0.477, 95% CI: 0.295–0.772, p = 0.002; IBC vs. IC: HR = 0.479, 95% CI: 0.292–0.784, p = 0.003). IBC also showed a numerically longer OS than IC (18.99 months vs. 12.52 months; HR = 0.692, 95% CI: 0.429–1.114, p = 0.128), although this difference did not reach statistical significance. Subgroup analyses, conducted as pre‐specified exploratory analyses, showed that patients with male gender, smoking history, brain metastasis, polymetastases and low PD‐L1 expression (< 50%) displayed superior PFS when treated with IBC compared with their counterparts. Besides, IBC showed comparable adverse events relative to IC and BC treatments. Conclusions: IBC treatment showed superior efficacy in oncogene wild‐type lung adenocarcinoma patients with liver metastases, especially in those with male gender, smoking history, brain metastasis, polymetastases, and low PD‐L1 expression.

  • Open Access

    Efficacy of surufatinib in advanced Grade 3 neuroendocrine tumors: a real-world, national, multicenter study

    by Jian Wang, Ning Zhang, Yun Liang, Jiang Long, Yihebali Chi, Suzhen Zhang, Chunmei Bai, Yu Wang, Yinying Wu, Hanguang Hu, et al.

    Background: Well-differentiated Grade 3 neuroendocrine tumors (G3 NETs) represent a heterogeneous entity with limited therapeutic standards. Surufatinib, a small-molecule inhibitor, has shown efficacy in G1/G2 NETs, but its specific role in the G3 subpopulation and optimal patient selection strategies remain to be elucidated. Objectives: This study aimed to evaluate the real-world efficacy of surufatinib in G3 NETs and identify the factors that influenced progression-free survival (PFS). Design: A national, multicenter, retrospective observational study. Methods: We analyzed data from 77 patients with unresectable or metastatic G3 NETs (Ki-67 > 20%) treated with surufatinib across 15 centers in China between January 2021 and April 2024. The reporting of this study conforms to the STROBE statement. The primary endpoint was PFS. A multivariable Cox proportional hazards model was used to explore prognostic factors. Results: The median Ki-67 index was 30% (range: 22%−70%), and 49 patients were of pancreatic origin. A total of 11 patients were treatment-naïve, and 27 patients received surufatinib-based combination therapy. The overall median PFS was 9.4 months (95% confidence interval: 8.5–13.0), and the objective response rate (ORR) was 22.1%. Patients with a Ki-67 index ⩽ 30% had longer PFS than the Ki-67 > 30% group (12.6 vs 9.0 months, hazard ratio = 0.270, p = 0.003). Combined treatment showed a numerical trend toward improved ORR (33.3% vs 16.0%, p = 0.08), but did not significantly prolong PFS compared to surufatinib monotherapy (9.7 vs 9.4 months, p = 0.64). Conclusion: Surufatinib was a promising therapeutic option for G3 NETs. Prospective, larger-scale cohorts are warranted to confirm the efficacy and address the predictive markers for better patient selection.

  • Open Access

    Efficacy and safety of novel immune checkpoint inhibitor‐based combinations versus chemotherapy as first‐line treatment for patients with extensive‐stage small cell lung cancer: A network meta‐analysis

    by Chuang Yang, Tiantian Xuan, Qing Gong, Xin Dai, Chengjun Wang, Rongyu Zhang, Wen Zhao, Jian Wang, Weiming Yue, Jisheng Li

    Background: Patients with extensive‐stage small cell lung cancer (ES‐SCLC) have an exceptionally poor prognosis and immune checkpoint inhibitors (ICIs) combined with etoposide‐platinum is recommended as standard first‐line therapy. However, which combination pattern is the best still remains unknown. This network meta‐analysis was performed to compare the efficacy and safety of currently available patterns including an antiangiogenic agent containing regimen and probed into the most appropriate therapy for patients.Methods: Hazard ratios (HRs) and odds ratios (ORs) were generated using R software. The outcomes of overall survival (OS), progression‐free survival (PFS), objective response rate (ORR), and adverse events of grade 3 or higher (grade ≥ 3 adverse events [AEs]) were analyzed.Results: A total of 10 randomized controlled trials (RCTs) involving 5544 patients were included for analysis. Drug combination patterns included adebrelimab, atezolizumab, durvalumab, durvalumab plus tremelimumab, ipilimumab, pembrolizumab, serplulimab, benmelstobart plus anlotinib, tislelizumab, tiragolumab plus atezolizumab and toripalimab in combination with chemotherapy. The novel antiangiogenic agent containing regimen benmelstobart + anlotinib + chemotherapy showed the highest possibility to present the best PFS and OS versus chemotherapy. Compared with ICI plus chemotherapy, it also achieved significantly better PFS and presented a tendency of OS benefit. As for safety and toxicity, patients treated with benmelstobart + anlotinib + chemotherapy and durvalumab + tremelimumab + chemotherapy suffered a higher likelihood of more grade ≥ 3 AEs without unexpected AEs.Conclusion: PD‐1/PD‐L1 inhibitors‐based combinations are associated with significant improvement in both PFS and OS for treatment‐naïve ES‐SCLC patients. Benmelstobart plus anlotinib with chemotherapy (CT) yielded better survival benefit versus CT alone or other ICIs + CT with caution for more adverse effects along with the addition of an antiangiogenic agent.


  • Open Access

    Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease

    by Xin Tong, Yu Song, Shengxia Yin, Jian Wang, Rui Huang, Chao Wu, Junping Shi, Jie Li

    Chronic hepatitis B (CHB) virus infection is an important threat to global health despite the administration of vaccines and the use of antiviral treatments. In recent years, as the prevalence of obesity and metabolic syndrome has increased, non-alcoholic fatty liver disease (NAFLD) in patients with CHB has become more common. Both diseases can lead to liver fibrosis and even hepatocellular carcinoma, but the risk of dual etiology, outcome, and CHB combined with NAFLD is not fully elucidated. In this review, we assess the overlapping prevalence of NAFLD and CHB, summarize recent studies of clinical and basic research related to potential interactions, and evaluate the progressive changes of treatments for CHB patients with NAFLD. This review increases the understanding of the relationship and mechanisms of interaction between steatosis and hepatitis B virus infection, and it provides new strategies for the future clinical management and treatment of CHB combined with NAFLD.


  • Open Access

    AB045. P-13. Genomic heterogeneity between Asian and Western intrahepatic cholangiocarcinoma

    by Reham Abdel-Wahab, Siqin Liu, Jingyu Cao, Jing Hu, Funda Meric-Bernstam, Junjie Xu, Qiang Li, Maolin Yan, Yujie Feng, Jianzhen Lin, et al.

    Background: Intrahepatic cholangiocarcinoma (IHCCA), a global health problem, is rising in incidence and has differing etiologies worldwide. Next-generation sequencing (NGS) showed that IHCCA is enriched with a relatively high number of actionable mutations with a promising novel targeted therapies anti-tumor activity. However, NGS data from Asia where IHCCA is most prevalent are very limited. Methods: Comprehensive genomic profiling using NGS on 164 Asian and 283 Western IHCCA paraffin-embedded tumor was performed. We measured the distribution of DNA repair genetic aberrations (GAs) along with coexisting actionable mutations. We classified our patients according to the tumor mutation burden (TMB) score into: TMB-low (10 mutations/Mb). Then, we assessed the association between DNA repair GAs and TMB. Results: Among Asian cohort, 118 patients (72%) had ≥1 actionable GA with significantly higher frequency in KMT2C, BRCA1/2, and DDR2 as compared with Western patients (P=0.02, 0.003, and 0.003, respectively). In Western cohort, 154 patients (60.9%) had >1 actionable GA with higher frequency of CDKN2A/B and IDH1/2 GAs (P=0.0004 and Conclusions: Comprehensive genomic profiling of IHCCA suggests a higher TMB-high and DNA repair mutation frequency in Asian as compared with the Western patients. Future clinical trials should account for this genetic heterogeneity.


  • PLGA–PTMC–Cultured Bone Mesenchymal Stem Cell Scaffold Enhances Cartilage Regeneration in Tissue‐Engineered Tracheal Transplantation

    by Bingyang Yan, Zhipei Zhang, Xiaoping Wang, Yunfeng Ni, Yongshi Liu, Tao Liu, Wuping Wang, Hao Xing, Ying Sun, Jian Wang, et al.

    The treatment of long‐segment tracheal defect requires the transplantation of effective tracheal substitute, and the tissue‐engineered trachea (TET) has been proposed as an ideal tracheal substitute. The major cause of the failure of segmental tracheal defect reconstruction by TET is airway collapse caused by the chondromalacia of TET cartilage. The key to maintain the TET structure is the regeneration of chondrocytes in cartilage, which can secrete plenty of cartilage matrices. To address the problem of the chondromalacia of TET cartilage, this study proposed an improved strategy. We designed a new cell sheet scaffold using the poly(lactic‐co‐glycolic acid) (PLGA) and poly(trimethylene carbonate) (PTMC) to make a porous membrane for seeding cells, and used the PLGA–PTMC cell‐scaffold to pack the decellularized allogeneic trachea to construct a new type of TET. The TET was then implanted in the subcutaneous tissue for vascularization for 2 weeks. Orthotopic transplantation was then performed after implantation. The efficiency of the TET we designed was analyzed by histological examination and biomechanical analyses 4 weeks after surgery. Four weeks after surgery, both the number of chondrocytes and the amount of cartilage matrix were significantly higher than those contained in the traditional stem‐cell–based TET. Besides, the coefficient of stiffness of TET was significantly larger than the traditional TET. This study provided a promising approach for the long‐term functional reconstruction of long‐segment tracheal defect, and the TET we designed had potential application prospects in the field of TET reconstruction.


  • Open Access

    Impact of Chemotherapy-Related Hyperglycemia on Prognosis of Child Acute Lymphocytic Leukemia

    by Bi-Hong Zhang, Jian Wang, Hong-Man Xue, Chun Chen

    To investigate the impact of hyperglycemia during inductive treatment on the prognosis of acute lymphocytic leukemia (ALL) in children. Clinical data of 159 ALL childhood cases were reviewed. The patients were divided into the hyperglycemia group (fasting glucose≥126 mg/dl and/or random blood glucose≥200 mg/dl) and the euglycemia group according to the blood glucose values. The ?2 test was performed to compare the complete remission rates of the two groups, and Kaplan-Meier and log-rank tests were performed to compare the 5-year overall and relapse-free survival. The incidence of hyperglycemia in the age≥10-year-old group was higher than the younger-age group (P=0.009). Values in the interim- and high-risk groups were higher than the standard-risk group (P=0.028), while there was no significant difference between genders (P=0.056). The complete remission rates of the 2 groups demonstrated no significant difference (P=0.134), while the 5-year OS of the hyperglycemia group was lower than in the euglycemia group (83.8±6.0% vs 94.9±2.4%, P=0.014). The 5 -year RFS was significantly lower than the euglycemia group (62.9±8.7%) vs 80.2±9.1%, P<0.001). Children with age≥10 years old, and in the middle- and high-risk groups appear prone to complicating hyperglycemia during inductive chemotherapy, associated with lower 5-year OS and RFS.